PYC Therapeutics (ASX: PYC) released its September 2026 investor update showing a quarterly loss of $0.0233 per share against a forecast of $7.60. Revenue for the period was $28.64 million. The shares traded at $2.57, close to the 52‑week high of $2.62, and rose 2.65% in after‑hours trading.
The company highlighted progress on its lead polycystic kidney disease (PKD) candidate, PYC-003. Doses of 1.2 mg/kg and 2.4 mg/kg administered every six weeks maintained 100% exposure above the minimum effective concentration at month four, compared with 70% and 90% for single doses. Patient‑derived models showed restoration of PC1 protein to roughly 85% of wild‑type levels. The Phase 1/2 trial has enrolled 13 of 24 patients in the multiple ascending dose cohort, with 24 patients overall. Data through four months of follow‑up are expected in Q4 2026–Q1 2027, with 12‑month total kidney volume (TKV) readouts targeted for late 2027.
Other pipeline assets were also updated. PYC-002, aimed at Phelan‑McDermid syndrome, is on track for an IND submission in 2027, with proof‑of‑concept efforts slated for 2028. PYC-001, targeting autosomal dominant optic atrophy, and VP-001 for retinitis pigmentosa type 11 are progressing toward proof‑of‑concept milestones in 2028.
PYC announced several senior appointments in 2026. A new chief financial officer and a combined general counsel/co‑company secretary joined in Q2, while a chief clinical development officer and a program lead for Phelan‑McDermid syndrome were added in Q3.
Looking ahead, the company expects multiple ascending dose data through 12 months of follow‑up in Q2–Q4 2027, an open‑label extension for VP-001, and the start of registrational trials for PYC-003 in 2028. Management also referenced a potential dual‑listing structure under consideration since 2025.
